{
    "nct_id": "NCT03235544",
    "official_title": "A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)",
    "inclusion_criteria": "* Men and women, aged 18 years or older.\n* Documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.\n* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of central nervous system lymphoma (either primary or metastatic).\n* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan PI3K inhibitor.\n* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.\n* Active graft-versus-host disease.\n* Liver disease: Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).",
    "miscellaneous_criteria": ""
}